摘要
以ＤＯＴＡ类双功能螯合剂（ＤＯＴＡ－Ｐｅｐｔｉｄｅ）为联接剂，采用先把９０Ｙ标记到联接剂上，经纯化后再与单克隆抗体偶联的９０Ｙ预标记方法，使放射性得率大于３０％，并确定了标记产物的分析方法。结果表明使用９０Ｙ预标记方法把９０Ｙ标记到单克隆抗体上的过程是合理的，最终产品的放射化学纯度经ＨＰＬＣ和ＴＬＣ测定均大于９５％，相对于１２５Ｉ－ｌｙｍ－１的免疫活性经体外细胞结合法测定都大于１００％。
The optimum labelling condition was established for using a new bifunctional chelating agent (DOTA-Peptide) in 90Y-labelled monoclonal antibody Lym-1 by the pre-labelling method, in which the 90Y was first labelled to the bifunctional chelating agent and then conjugated to the monoclonal antibody. The results showed that the radiolabelling procedure was reasonable and the radioactivity yield in products was satisfactory. The radiochendcal purity of 90Y-labelled Lym-1 was determined to be over 95% by gel filtration HPLC and silica gel TLC. The immunoreactivity of the final product was found to be greater than 100% relative to 125I-Lym-1 (as a standard) by in vitro cell binding assay.
出处
《核技术》
CAS
CSCD
北大核心
1996年第7期440-444,共5页
Nuclear Techniques
关键词
^90Y
双功能螯合剂
单克隆抗体
标记
Yttrium-90
Bifunctional chelating agent
Monoclonal antibody
Labelling
